WO1991008242A1 - Procede d'obtention de copolymeres par greffage de motifs vinyliques et copolymeres greffes resultants - Google Patents

Procede d'obtention de copolymeres par greffage de motifs vinyliques et copolymeres greffes resultants Download PDF

Info

Publication number
WO1991008242A1
WO1991008242A1 PCT/FR1990/000858 FR9000858W WO9108242A1 WO 1991008242 A1 WO1991008242 A1 WO 1991008242A1 FR 9000858 W FR9000858 W FR 9000858W WO 9108242 A1 WO9108242 A1 WO 9108242A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
copolymers
vinyl
compound
peptide
Prior art date
Application number
PCT/FR1990/000858
Other languages
English (en)
French (fr)
Inventor
Charles Baquey
Marie Yolande Bernasconi
Thierry Darnis
Original Assignee
Institut National De La Sante Et De La Recherche Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale filed Critical Institut National De La Sante Et De La Recherche Medicale
Publication of WO1991008242A1 publication Critical patent/WO1991008242A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F289/00—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds not provided for in groups C08F251/00 - C08F287/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof

Definitions

  • the invention relates to a process for obtaining copolymers by grafting vinyl units and the resulting bioactive copolymers.
  • copolymers comprising at least one molecule having a biological activity, associated by irreversible bond to a macromolecular material, by means of grafted units of one or more vinyl monomers.
  • copolymer has been studied to develop, for example, vascular prostheses or even active phases usable in affinity chromatography.
  • some of the co-inventors of the present application have attempted to combine heparin by radiochemical grafting, using vinyl monomers on a polymer material constituted by a polyester, to form a vascular prosthesis (Baquey et al. Innov. Tech. Biol. Med. vol 2, n ° 4 1981, 379-389).
  • the object of the invention is therefore to provide a process for obtaining bioactive copolymers ensuring better maintenance of the conformational freedom of the biological molecule and, thereby, of its biological activity.
  • the invention further relates to the biological applications of these copolymers for the preparation, for example, of vascular prostheses or of active phases usable in affinity chromatography.
  • the process for obtaining the bioactive copolymers of the invention is characterized in that at least one compound A chosen from a protein, a peptide, a protein or peptide derivative and a synthetic or natural material B is subjected simultaneously to radiochemical, chemical or photochemical treatment, in the presence of one or more vinyl monomers, of at least one homopolymerization inhibitor and of a crosslinking agent, so as to obtain the grafting of the units of vinyl origin, by irreversible association on A and B and the crosslinking of the vinyl motifs.
  • at least one compound A chosen from a protein, a peptide, a protein or peptide derivative and a synthetic or natural material B is subjected simultaneously to radiochemical, chemical or photochemical treatment, in the presence of one or more vinyl monomers, of at least one homopolymerization inhibitor and of a crosslinking agent, so as to obtain the grafting of the units of vinyl origin, by irreversible association on A and B and the crosslinking of the vinyl motifs.
  • a protein In general, use is made of a protein, a peptide or one of their derivatives endowed with a biological activity having a particular affinity for a given molecular or cellular ligand, for example a cellular receptor.
  • collagen is advantageously used as protein A.
  • collagen of bovine origin containing a preponderant proportion of type I collagen is used.
  • coagulation proteases such as antithrombin III (AT III), or pro-activator of fibrinolysis, an inhibitory action on platelet adhesion such as albumin, or alternatively a mediating action of fibrinolysis or a mediating action of cell adhesion and growth.
  • urokinase tissue plasminogen activator (tpA) streptokinase.
  • tpA tissue plasminogen activator
  • Proteins promoting cell attachment and / or intervening in the organization of the extracellular matrix of tissues such as fibronectin or laminin, used where appropriate in conjunction with other proteins, for example collagen, make it possible to have copolymers which promote cell attachment.
  • proteins include elastin or growth factors.
  • the proteins used according to the invention can be in admixture with other compounds, for example with proteoglycans and / or glycosaminoglycans.
  • the protein derivatives are for example glycoproteins or else lipoproteins.
  • proteins which can be used in affinity chromatography techniques such as specific immunoglobulins or even antithrombin III.
  • affinity chromatography techniques such as specific immunoglobulins or even antithrombin III.
  • peptides suitable for implementing the invention mention will be made of those of interest in controlling cell adhesion and having or corresponding to particular sequences playing a role in the adhesion of cells to the extracellular matrix. In view of their properties, such peptides are advantageously incorporated into the structure of surfaces intended to be colonized by cells.
  • One such peptide sequence recognized by cell adhesion receptors is of the arg-gly-asp type.
  • This tripeptide sequence can be used alone, in a synthetic peptide or in a repeating sequence.
  • the macromolecular material B is of synthetic or natural origin.
  • REPLACEMENT SHEET Synthetic materials which are particularly advantageous for the biological applications of these copolymers include polymers such as polyesters, polyurethanes, fiber-forming polymers.
  • the material B linked to A constitutes a coating on the surface of another type of material. The covalent bond therefore only involves the macromolecular network of the surface coating.
  • Natural macromolecular materials include, for example, cellulose, agarose, dextran, starch.
  • the vinyl monomer is chosen from acrylic or methacrylic acid or acrylates and methacrylates of alkyl and hydroxyalkyl, in particular from C 1 to C 4, in particular methyl, derivatives of these compounds such as acrylamide or acrylonitrile .
  • the vinyl monomer can be formed by multivinyl compounds.
  • the grafting is carried out by any suitable radiochemical, chemical or photochemical means.
  • the grafting is carried out according to a radiochemical process.
  • radioactive sources emitting gamma rays allows easy grafting.
  • the dose delivered is at least 1 kilogray.
  • the dose rate is approximately 3 kilograys / hour.
  • the grafting rates can be limited, which makes it possible to better maintain the conformational freedom of A and therefore its biological activity.
  • the crosslinking agent allows the branching and crosslinking of growing homopolymer chains. The probability of bridging between compounds A and B is thereby increased.
  • crosslinking agents As suitable crosslinking agents, mention will be made of agents comprising at least two vinyl double bonds such as ethylene dimethacrylate or bis-acrylamide.
  • the grafting is preferably carried out in the liquid phase.
  • the macromolecular material B is immersed in an aqueous solution containing the compound A, a vinyl or multivinyl monomer, the homopolymerization inhibitor and the crosslinking agent.
  • the proportions of reagents making it possible to obtain the satisfactory mechanical properties of the macromolecular material and an unchanged macroscopic appearance correspond to the use, as a percentage by weight, of the vinyl derivative at a rate of 15 to 25%, of the homopolymerization inhibitor to from 5 to 10% approximately, of the crosslinking agent at 0.001% to 0.25%, compound A representing approximately 30%, the remainder being water.
  • the homopolymerization inhibitor is a salt, for example a copper or iron salt, such as CuSO4 or Fe SO4.
  • the grafting can be carried out photochemically or alternatively chemically, for example using redox systems such as the Ce III + / Ce IV + pair.
  • the invention also relates, as new products, to the graft copolymers as obtained by implementing the process defined above.
  • copolymers are characterized in that they comprise a compound A chosen from a protein, a peptide, a protein derivative or a peptide derivative, associated by covalent bond to a macromolecular material B via polymeric links such as resulting grafting of vinyl type monomers or of a mixture of such monomers, forming a network by means of a vinyl crosslinking agent.
  • copolymers of the invention are ternary copolymers of protein A type / links of crosslinked vinyl origin / macromolecular material B.
  • Protein A is formed by a protein of a given type or comprises several proteins chosen according to the applications envisaged.
  • the macromolecular material can be formed of a single type of material or of composite materials or of complex structure in which only the surface serves as a support for protein A.
  • compound A is a protein derivative, a peptide or a protein or peptide derivative as already defined.
  • copoly ⁇ mers of the invention are specially suitable for the development of vascular prosthesis substitutes.
  • copolymers of the invention include the development of active phases which can be used in affinity chromatography, in particular for the purification of biological molecules or for carrying out cell sorting and including heparin Sepharose® and Protein A Sepharose represent particularly well-known examples.
  • active phases which can be used in affinity chromatography, in particular for the purification of biological molecules or for carrying out cell sorting and including heparin Sepharose® and Protein A Sepharose represent particularly well-known examples.
  • heparin Sepharose® and Protein A Sepharose represent particularly well-known examples.
  • REPLACEMENT SHEET Similarly, the fixing of ATIII on a support B. makes it possible to have a material for separating heparin or heparin fragments from a given medium or products having an activity modeled on that of heparin.
  • the ability of compound A to be recognized by the molecules of the medium to be analyzed makes it possible to carry out separations with high yields.
  • the molecules of A linked to the support B to which they bring a specific affinity for a given molecule, or a given cell type retain their functional integrity better than when they are linked according to the chemical processes of the prior art.
  • polyester samples Preparation of polyester samples The prostheses are cut into samples, weighed, washed with boiling distilled water in a soxhlet apparatus until constant mass.
  • the acrylic acid supplied by MERCK contains 200 ppm of hydroquinone as a polymerization inhibitor. This inhibitor can be removed by distillation of the monomer which is then stored under vacuum in ampoules at -80 ° C.
  • Collagen of bovine origin is presented in lyophilized form, supplied by ORGANOTECHNICS.
  • a 10-2 mol / l aqueous solution of copper sulphate is produced. Added to the reaction medium, it makes it possible to avoid excessive homopolymerization of the monomer (s) in solution during the irradiation.
  • the crosslinking agent is stored at + 4 ° C. and used as it is at very low concentration. .
  • a grafting solution containing 15 to 30% of acrylic acid, 5 to 10% of a 10 ⁇ 2M solution of CuSO 4, 5H20, 40% of collagen solution, 0.01% to 0.25% of is used.
  • crosslinking agent with 100% water is used.
  • the polyester samples are placed in a glass enclosure containing the homogenized grafting solution.
  • the contents of the cell are degassed by 4 successive cycles of freezing - pumping - thawing.
  • Freezing is carried out by immersion of the enclosure in liquid nitrogen (-196 ° C).
  • the vacuum is achieved using a vane pump.
  • the cell is thawed in a water bath at • 37 ° C.
  • the number of cycles performed depends on the amount of solution to be degassed.
  • the quality of degassing is assessed visually.
  • Cellophane 1 / acrylic acid / albumin or collagen.
  • the affinity of the treated material, for the platelets on the one hand, and for fibrinogen on the other hand is modified compared to that of the starting polyester.
  • a first series of samples (series A) is rinsed with the solvent buffer until a constant value of their residual radioactivity is obtained; then, the rinsing is continued with an albumin solution of the same concentration as the solution used during the incubation, but free of radioactive tracer. There is then a decrease in the residual radioactivity of the samples, proving an exchange of pre-adsorbed albumin molecules, and possibly labeled, with cold albumin molecules.
  • Example 2 The samples are then rinsed with water and then with an albumin solution without radioactive tracer like the samples of series A. There is practically no reduction in their residual radioactivity, which leads to the conclusion that the irreversible association of
  • EXAMPLE 4 BIOLOGICAL CHARACTERIZATION. Culture of human endothelial cells (CEH) in the presence of extracts of copolymers of the invention (collagen / acrylic acid / Dacron®).
  • grafted samples according to the invention and ungrafted samples are sterilized with 25 kilogray gamma rays.
  • the extracts of tested materials are prepared from samples immersed for 120 hours at 37 ° C in physiological saline (0.9% NaCl).
  • the volume of serum used is such that the ratio of the surface area of the sample to this volume is equal to 5 cm2 / ml.
  • the final concentration of the extract in the culture medium is 10% (vol / vol).
  • the CEH are isolated from umbilical cord veins according to the method described by Jaffe in Transplantation proceedings 1980 (Sept) XII, n ° 3 Suppl-1, 49-53.
  • the cells are inoculated into containers containing several wells at a starting density of 7.5 ⁇ 10 3 cells / cm 2.
  • the cells are maintained at 37 "C under 5% C02 and the culture medium is renewed every day.
  • 37 ° C under 5% CO 2 and the culture medium is renewed every day e.
  • the biocompatibility of the copolymer is evaluated by cell attachment (after 3 to 6 hours), proliferation and the protein content of the cells.
  • the cells are rinsed and then lysed in distilled water using five freeze-thaw cycles.
  • the total protein content (in ug / 105 cells) is determined according to the technique known as Pierce BCA protein assay (Interchim, Paris). For specific biocompatibility, the intracellular presence of factor VIII (FVIII) is revealed by immunofluorescence in the controls and the series tested on the 6th day of proliferation.
  • FVIII factor VIII
  • the CEH express and maintain their characteristics, namely the synthesis of FVIII antigen, even in the presence of extracts of copolymer materials according to the invention.
  • phase chosen is SEPHADEX ® G 25 (crosslinked Dextran) and the protein albumin.
  • Sephadéx ® (1 g) is swelled in an albumin solution (7.0 mg / ml) accompanied by albumin labeled with iodine 125 in physiological phosphate buffer (PBS)
  • the final suspension is degassed under a vacuum of 5.102 torr, then irradiated until absorption of 1 Mrad at a dose rate of 0.3 Mrad.h-1 approximately.
  • the Sephadex® gel is recovered by decantation and then extracted with a soxhlet using a 1: 1 mixture (methanol / water) for 5 days.
  • the radioactivity measurements make it possible to calculate a retention rate of 1.03 mg / g of dry Sephadex®, which is 8 times more than the quantity retained when the Sephadex® exposed to the albumin solution is not irradiated and rinsed with 100 ml of water only (no hot extraction).
  • the invention therefore provides graft copolymers of high stability, the structure of which makes it possible to take full advantage of the biological activity of the compound of protein or peptide type, which is of major interest in the various biological applications where these copolymers are found. appropriate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Graft Or Block Polymers (AREA)
  • Materials For Medical Uses (AREA)
PCT/FR1990/000858 1989-11-27 1990-11-27 Procede d'obtention de copolymeres par greffage de motifs vinyliques et copolymeres greffes resultants WO1991008242A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR89/15575 1989-11-27
FR8915575A FR2655048A1 (fr) 1989-11-27 1989-11-27 Procede d'obtention de copolymeres bioactifs par greffage de motifs vinyliques et copolymeres greffes resultants.

Publications (1)

Publication Number Publication Date
WO1991008242A1 true WO1991008242A1 (fr) 1991-06-13

Family

ID=9387817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1990/000858 WO1991008242A1 (fr) 1989-11-27 1990-11-27 Procede d'obtention de copolymeres par greffage de motifs vinyliques et copolymeres greffes resultants

Country Status (2)

Country Link
FR (1) FR2655048A1 (enrdf_load_stackoverflow)
WO (1) WO1991008242A1 (enrdf_load_stackoverflow)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0488258A3 (en) * 1990-11-27 1993-05-05 Fuji Photo Film Co., Ltd. Propenamide derivatives, polymers, copolymers and use thereof
FR2713488A1 (fr) * 1993-11-24 1995-06-16 Aspid Sa De Cv Composition présentant un effet anti-fibrotique, à base de collagène polymérisé.
ES2079311A1 (es) * 1993-11-30 1996-01-01 Aspid S A De C V Una composicion anti-fibrotica a base de la colagena polimerizada
WO1999054729A3 (de) * 1998-04-22 2000-02-17 Biotechnolog Forschung Gmbh Immobilisierte substrate, trenngele und verfahren zum nachweis von enzymaktivitäten
WO2001080921A3 (en) * 2000-04-20 2002-02-28 Univ Emory Native protein mimetic fibers, fiber networks and fabrics for medical use
US6506895B2 (en) 1997-08-15 2003-01-14 Surmodics, Inc. Photoactivatable nucleic acids

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
US6121027A (en) * 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
WO2005039641A2 (en) * 2003-10-15 2005-05-06 The Regents Of The University Of California Biomacromolecule polymer conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2211507A1 (enrdf_load_stackoverflow) * 1972-12-22 1974-07-19 Unisearch Ltd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU883052A1 (ru) * 1979-11-14 1981-11-23 Всесоюзный кардиологический научный центр АМН СССР Иммуносорбент

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2211507A1 (enrdf_load_stackoverflow) * 1972-12-22 1974-07-19 Unisearch Ltd

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 109, no. 8, 22 août 1988, (Columbus, Ohio, US), Y. Imanishi et al.: "Design and synthesis of biocompatible polymeric materials", voir page 435 *
Chemical Abstracts, vol. 75, no. 16, 18 octobre 1971, (Columbus, Ohio, US), voir page 21 *
Chemical Abstracts, vol. 84, no. 4, 26 janvier 1976, (Columbus, Ohio, US), N.G. Gaylord et al.: "Donor-acceptor complexes in copolymerization. LII. Alternating copolymer graft copolymers. IX. Grafting of poly(styrene-alt-acrylonitrile) onto starch, casein, and collagen", voir page 22 *
Chemical Abstracts, vol. 96, no. 21, 24 mai 1982, (Columbus, Ohio, US), voir pages 375-376 *
Polymer Science, U.S.S.R., vol. 2, no. 3, 1961, L. Kiss et al.: "Graft copolymerization of methzl methacrylate and styrene on to gelatin induced by ionizing radiation", pages 308-309 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0488258A3 (en) * 1990-11-27 1993-05-05 Fuji Photo Film Co., Ltd. Propenamide derivatives, polymers, copolymers and use thereof
FR2713488A1 (fr) * 1993-11-24 1995-06-16 Aspid Sa De Cv Composition présentant un effet anti-fibrotique, à base de collagène polymérisé.
ES2079311A1 (es) * 1993-11-30 1996-01-01 Aspid S A De C V Una composicion anti-fibrotica a base de la colagena polimerizada
US6506895B2 (en) 1997-08-15 2003-01-14 Surmodics, Inc. Photoactivatable nucleic acids
WO1999054729A3 (de) * 1998-04-22 2000-02-17 Biotechnolog Forschung Gmbh Immobilisierte substrate, trenngele und verfahren zum nachweis von enzymaktivitäten
WO2001080921A3 (en) * 2000-04-20 2002-02-28 Univ Emory Native protein mimetic fibers, fiber networks and fabrics for medical use

Also Published As

Publication number Publication date
FR2655048B1 (enrdf_load_stackoverflow) 1995-02-24
FR2655048A1 (fr) 1991-05-31

Similar Documents

Publication Publication Date Title
Martinez et al. Effects of crosslinking on the mechanical properties, drug release and cytocompatibility of protein polymers
JPH05502998A (ja) 望ましい細胞接着効果をもつ表面
Sperling et al. Covalently immobilized thrombomodulin inhibits coagulation and complement activation of artificial surfaces in vitro
Li et al. Recruitment of multiple cell lines by collagen-synthetic copolymer matrices in corneal regeneration
Grzesiak et al. Enhancement of cell interactions with collagen/glycosaminoglycan matrices by RGD derivatization
JPH05269198A (ja) 複合化人工血管
WO1991008242A1 (fr) Procede d'obtention de copolymeres par greffage de motifs vinyliques et copolymeres greffes resultants
EP0485491A1 (fr) Membrane biologique artificielle.
Wang et al. The effect of hirudin modification of silk fibroin on cell growth and antithrombogenicity
US20110091443A1 (en) Heparin-conjugated fibrin gel and method and kit for preparing same
Horbett Selected aspects of the state of the art in biomaterials for cardiovascular applications
CA2960408C (en) Medical devices with reduced thrombogenicity
Jin et al. Poly (ferulic acid)-hybrid nanofibers for reducing thrombosis and restraining intimal hyperplasia in vascular tissue engineering
HORBETT Biological Activity of
Huebsch et al. Photoreactive analog of peptide FN‐C/H‐V from the carboxy‐terminal heparin‐binding domains of fibronectin supports endothelial cell adhesion and spreading on biomaterial surfaces
CA2582306C (fr) Greffage covalent de substances hydrophobes sur le collagene
Imanish et al. Design and synthesis of biocompatible polymeric materials
EP0217816B1 (fr) Produit a base d'elastine, procede pour sa preparation et ses applications biologiques, en particulier en tant que biomateriaux et supports artificiels
CN116196487A (zh) 一种涂层及带有该涂层的支架、其制备方法和应用
Sipehia et al. In vivo evaluaton of ammonia plasma modified ePTFE grafts for small diameter blood vessel replacement: A preliminary report
CN104874031B (zh) 模拟人体纤溶系统和血管内皮系统的聚氨酯衍生物及制备方法及相关产物制备方法
Huang et al. Integrated hydrogel of fucoidan and rhCol III for bioprosthetic heart valves to promote the antithrombosis, anti-inflammatory, and anti-calcification properties
Frautschi et al. Alkylation of cellulosic membranes results in reduced complement activation
US20190275214A1 (en) Medical devices with reduced thrombogenicity
Yang et al. Nitrate-Functionalized poly (e-Caprolactone) Small-Diameter Vascular Grafts Enhance Vascular Regeneration via Sustained Release of Nitric Oxide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA